Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Round Table Case-Based Discussion -- Drs. Laskin and Sandler on First Line and Maintenance Chemo
Author
Howard (Jack) West, MD

This is a continuation of the round table format, discussing real life case management with my colleagues who are lung cancer experts at other institutions, This case is the second half of discussion centered around a never-smoking Asian woman who doesn't have an EGFR mutation, and specifically the decision-making process of what first line chemotherapy-based treatment to recommend and whether to continue with maintenance therapy. My guests for the discussion are Drs. Janessa Laskin, medical oncologist from British Columbia Cancer Agency in Vancouver, BC, and Alan Sandler, medical oncologist and Director of Hematology/Oncology at Oregon Health & Science University in Portland.

Here is the video version, audio, transcript, and associated figures.

[powerpress]

rt-laskin-sandler-never-smoker-egfr-wt-1st-line-chemo-and-maint-rx-audio-podcast

rt-laskin-sandler-never-smoker-egfr-wt-1st-line-chemo-and-maint-rx-transcript

rt-laskin-sandler-never-smoker-egfr-wt-1st-line-chemo-and-maint-rx-figures

I'll have another case from the same round table with Drs. Laskin and Sandler soon. In the meantime, we are happy to review your own cases and questions if you would like to submit them and have questions that are timely and potentially relevant to a broad audience in the cancer community. So if you're interested, please e-mail a brief synopsis and perhaps your central question(s) to west@cancergrace.org for consideration.

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora